Madam Speaker, my colleague is a well-versed member of the public accounts committee and has done great work there on behalf of many Canadians, and I thank her for that.
One of the issues we dealt with in the public accounts committee was hearing from companies, particularly from pharmaceutical companies during the time of COVID. We have seen that these pharmaceutical companies were malicious not only to Canadians, but they were malicious right across the globe. They sought to withhold consent to release documents and contracts. We saw that operators of these companies were hedging their bets. They were taking advantage of people because they had control over critical vaccine supply and critical vaccine patents and they used that to abuse countries right across the globe. In that public accounts committee, we reviewed those contracts, in the very first instance of that across the globe. Can the member please speak to the importance of transparency for these companies that would take advantage of a crisis?